SM
TOVX icon

Sabby Management’s Theriva Biologics TOVX Stock Holding History

Sabby Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-308
Closed -$25K – 124
2020
Q1 		$25K Sell
308
-2,441
-89% -$278K 0.01% 79
2019
Q4 		$348K Sell
2,749
-593
-18% -$63.1K 0.1% 40
2019
Q3 		$379K Sell
3,342
-273
-8% -$33K 0.2% 50
2019
Q2 		$497K Buy
3,615
+875
+32% +$126K 0.62% 32
2019
Q1 		$465K Sell
2,740
-1,730
-39% -$287K 0.22% 34
2018
Q4 		$626K Buy
+4,470
New +$1.06M 0.14% 44
2017
Q3 		– Sell
-19
Closed -$95K – 205
2017
Q2 		$95K Sell
19
-143
-88% -$712K 0.01% 195
2017
Q1 		$892K Sell
162
-185
-53% -$1.29M 0.05% 139
2016
Q4 		$2.31M Buy
+347
New +$3.56M 0.13% 92

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Sabby Management's TOVX Position: Q2 2020 in Review

Sabby Management sold out of Theriva Biologics (TOVX) in Q2 2020, closing a stake of 308 shares — an estimated $25K sold.

Sabby Management first reported a position in TOVX in Q4 2016 and held it in 9 quarters. The position peaked at $2.31M in Q4 2016. 19 funds tracked by Wall St. Rank hold TOVX as of Q2 2020.

  • Sabby Management reported no remaining Theriva Biologics position as of Q2 2020 after selling out during the quarter.
  • Sabby Management sold 308 Theriva Biologics shares in Q2 2020, an estimated $25K.
  • Sabby Management first reported a position in Theriva Biologics in Q4 2016 and held it in 9 quarters.
  • Sabby Management's Theriva Biologics position peaked at $2.31M in Q4 2016.
  • 19 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.